Finasteride Tablet, Film Coated
Product Images NDC 82009-061

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 82009-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line chart titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline with standard error for Finasteride and Placebo over four years. The chart compares symptom score changes over time from baseline to Year 4 with separate lines for Finasteride (decreasing trend) and Placebo (less decrease). Sample sizes at each timepoint are noted below the x-axis.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph showing the percent of patients having surgery for BPH, including TURP, over 48 months. The graph compares two groups: Finasteride and placebo, with Finasteride group showing a lower cumulative percentage of patients undergoing surgery compared to placebo. The chart also includes cumulative event numbers and patients at risk per year for both groups.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' showing the percent of patients over 48 months of observation time for two groups: Finasteride and Placebo. The Placebo group shows a higher cumulative percentage of patients affected over time compared to the Finasteride group, supported by a table of cumulative events and patients at risk per year for both groups below the graph.*

FDA Label Image

Figure4 (Finasteride Fig4)

Line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline over four years. Two lines represent placebo (circles) showing an increase in prostate volume, and finasteride (squares) showing a decrease that stabilizes from Year 1 to Year 4. Sample sizes for each group at each time point are listed below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group.' It shows percent with event on the Y-axis (0 to 25) and years from randomization on the X-axis (0 to 5.5). Four treatment groups are plotted: Placebo, Finasteride, Doxazosin, and Combination, each with distinct markers and increasing cumulative incidence over time.*

FDA Label Image

Package Label-principal Display Panel (5 mg (100 Tablets Bottle))

Label for Finasteride Tablets, USP 5 mg by Quallent Pharmaceuticals Health LLC. The oral film-coated tablets package contains 500 tablets. Manufactured by Aurobindo Pharma Limited in Hyderabad, India, for Quallent Pharmaceuticals Health LLC, Cayman Islands. Includes storage instructions, a warning against use by women or children, and other regulatory information.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure diagram of the active ingredient Finasteride, showing its steroid-like molecular framework and key functional groups as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.